

cancelled claims with instructions for entry pursuant to 37 C.F.R. §1.121 (c)(1)(i) is included beginning on page 2 of this communication. A marked-up version of the Specification's replacement paragraphs pursuant to 37 C.F.R. §1.121(b), as well as rewritten, added, and/or cancelled claims pursuant to 37 C.F.R. §1.121 (c)(1)(ii) is attached as Appendix I. A clean version of the entire set of pending claims pursuant to 37 C.F.R. §1.121 (c)(3) as they would appear following entry of this amendment is attached as Appendix II. None of the amendments to the Claims is intended to narrow the scope of any of the amended Claims within the meaning of *Festo*¹.

CLEAN VERSION OF REPLACEMENT PARAGRAPHS IN THE SPECIFICATION PURSUANT TO 37 C.F.R. §1.121(b) AND OF REWRITTEN, ADDED, AND/OR CANCELLED CLAIMS PURSUANT TO 37 C.F.R. §1.121 (c)(1)(i)

IN THE SPECIFICATION:

Please replace the Sequence Listing mailed on July 18, 2002, with a corrected Sequence Listing on pages 1-67 enclosed herewith.

IN THE CLAIMS:

Please cancel Claims 8-10, 35-38 and 40.

Please amend the Claims as follows:

2. (Twice Amended) A reduced allergenic variant of a polypeptide of interest, wherein said polypeptide of interest is selected from the group consisting of cellulases, lipases, endoglucosidase H, carbohydrases, reductases, oxidases, isomerases, transferases, kinases, and phosphatases, and said polypeptide of interest comprises a T-cell epitope,

¹ *Festo Corp. v. Shoketsu Kogyo Kabushiki Co.*, No. 95-1066, 2000 WL 1753646 (Fed. Cir. Nov. 29, 2000).

wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that one or more amino acid residues of the T-cell epitope are altered and

wherein an allergenic immunogenic response produced by said variant in an individual is less than said allergenic immunogenic response produced by said polypeptide of interest.